German assessments of two cancer medicines have used European JCA dossier evidence but not the completed EU reports, because national proceedings began before publication.
Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) has published benefit assessments of tarlatamab and lurbinectedin that reveal a timing gap between EU joint clinical assessment (JCA) reports and national assessment requirements. Both German proceedings began on 1 July; the European reports were not published until 8 July.
The assessments, issued on 1 October, concern two orphan medicines for small-cell lung cancer. Their manufacturers submitted German benefit-assessment dossiers that referred to evidence and analyses in the corresponding EU JCA dossiers. G-BA could use relevant information from those underlying submissions.
However, G-BA explicitly states that it did not take the completed EU JCA reports into account. Under the applicable German medicines benefit-assessment provisions, the reports were unavailable when the national procedures began. They therefore could not be used in the October assessments, even though publication followed one week after the German start date.
This differs from the proposition that Germany has already used the first completed JCA reports as the basis for these AMNOG assessments. The national and European processes have instead proceeded partly in parallel, with overlapping clinical evidence but without formal use of the final joint conclusions.
The October publications began national consultation, with final G-BA decisions expected in December. The cases show that the practical value of JCA for avoiding duplicated clinical review depends partly on when the EU report becomes available relative to national assessment milestones.
Source: Federal Joint Committee, Germany
Link: Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V – Tarlatamab (Benefit assessment of medicines with new active substances under Section 35a – tarlatamab)
Date: 1 October 2026
Source: Federal Joint Committee, Germany
Link: Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V – Lurbinectedin (Benefit assessment of medicines with new active substances under Section 35a – lurbinectedin)
Date: 1 October 2026
Source: European Commission
Link: Joint Clinical Assessment report on tarlatamab (Imdylltra)
Date: 8 July 2026
Please accept {{cookieConsents}} cookies to view this content